Samantha D’Anna
PhD
Senior Healthcare Management Consultant
Windsor, CT, US
Samantha D’Anna is a senior healthcare management consultant with the Hartford office of Milliman. She joined the firm in 2015.
Experience
Samantha provides consulting services to insurance companies, pharmacy benefit managers, Medicare plan sponsors, government entities, and nonprofit organizations.
Her primary work includes assisting Medicare Part D plan sponsors and other groups with strategic decisions around prescription drug plan pricing within the context of the current regulatory environment.
Publications and Presentations
- Co-author, Possible outcomes of potential disclosure requirements in Medicare Part D. Milliman White Paper, March 2023.
- Co-author, Self-reported health status of Medicare Part D beneficiaries. Millman Research Paper, November 2022.
- Co-author, Is Build Back Better Back? Overview of New Schumer Drug Pricing Reform. Milliman Briefing Note, July 2022.
- Co-author, A summary of insulin coverage in Medicare Part D. Milliman Report, June 2022.
- Co-author, Medicare Part D pharmacy price concessions at the point of sale. Milliman Report, February 2022.
- Co-author, A regulatory push to lower Part D costs at the pharmacy counter in 2023. Milliman Report, January 2022.
- Co-author, A demographic profile of Medicare Part D beneficiaries. Milliman White Paper, November 2021.
- Co-author, Reducing insulin costs for seniors: Thoughts for plan sponsors considering participation in the Medicare Part D Senior Savings Model. Milliman White Paper, March 2020.
- Co-author, A new Part D benefit design? Prescription Drug Pricing Reduction Act proposes major changes to Part D. Milliman White Paper, August 2019.
Education
- BA, Summa Cum Laude, Major: Psychology, Research Track, Minor: Neuroscience; University of Connecticut
- MA, Behavioral Neuroscience, University of Connecticut
- PhD, Behavioral Neuroscience, University of Connecticut
Publications
Read their latest work
Article
Pharmacy services administrative organization (PSAO) landscape
10 September 2024 - by Tory Carver, Tracy Margiott, Samantha D’Anna
We share the results of our count of pharmacy services administrative organizations for the Pharmaceutical Care Management Association.
Article
2021 Retail Pharmacy Reimbursement in Medicare Part D by Drug and Pharmacy Type
04 June 2024 - by Tory Carver, Samantha D’Anna, Tracy Margiott
We examine the 2021 retail pharmacy reimbursement in Medicare Part D by drug and pharmacy type.
Article
The shifting Medicare landscape: Results from 2024 open enrollment
02 May 2024 - by Samantha D’Anna, Tyler Engel, Katherine M. Holcomb
2024 brings significant changes to the Medicare Part D program, resulting in larger-than-average shifts in member enrollment.
Article
Possible outcomes of potential disclosure requirements in Medicare Part D
07 March 2023 - by Tory Carver, Samantha D’Anna, Tracy Margiott
Proposed legislation would require PBMs to publish Medicare Part D rebate information, potentially altering the strategies of stakeholders.
Article
Self-reported health status of Medicare Part D beneficiaries
09 November 2022 - by Samantha D’Anna, Nolan Kurtz
We look at the metrics of Medicare beneficiaries with prescription drug coverage across ethnicity, income, and education level in the individual Part D market.
Article
Is Build Back Better Back? Overview of New Schumer Drug Pricing Reform
22 July 2022 - by Michelle (Klein) Robb, Kevin Pierce, Samantha D’Anna, Jake K. Klaisner
We examine key provisions of Senator Schumer and the Senate Finance Committee’s new Prescription Drug Pricing Reform language, and compare with the Build Back Better Act’s previous version.
Article
A summary of insulin coverage in Medicare Part D
07 June 2022 - by Tory Carver, Samantha D’Anna, Tracy Margiott
Insulin products are widely covered on Part D formularies. In this analysis, all beneficiaries enrolled in an individual Medicare Part D plan have coverage in the classes noted, with a range of coverage options by manufacture and drug type.
Article
Medicare Part D pharmacy price concessions at the point of sale
18 February 2022 - by Tory Carver, Samantha D’Anna, Tracy Margiott
Under Medicare Part D, a proposed rule would require pharmacy DIR to be reflected in the negotiated price used at the point of sale for most drugs.
Article
A regulatory push to lower Part D costs at the pharmacy counter in 2023
28 January 2022 - by Cody Ball, Deana Bell, Samantha D’Anna, Tracy Margiott, Susan Silseth
A proposed change would require Medicare Part D plans to apply all price concessions they receive from a pharmacy network at the point of sale
Article
A demographic profile of Medicare Part D beneficiaries
08 November 2021 - by Samantha D’Anna, Nolan Kurtz
Understanding beneficiary characteristics helps key entities in the Part D program provide services that maximize value for the populations they serve.